Skip to main content

Clinical Trials Using Methotrexate

Review the clinical trials studying methotrexate on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 74

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients with High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Status: Active
Location: 198 locations
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients with Newly Diagnosed Osteosarcoma
Status: Active
Location: 170 locations
A Study to Compare Standard Chemotherapy to Therapy with CPX-351 and/or Gilteritinib for Patients with Newly Diagnosed AML with or without FLT3 Mutations
Status: Active
Location: 179 locations
A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Status: Active
Location: 201 locations
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia
Status: Active
Location: 429 locations
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy before Surgery for Patients with High-Grade Upper Urinary Tract Cancer
Status: Active
Location: 208 locations
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment with Blinatumomab for Children, Adolescents, and Young Adults with Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Status: Active
Location: 132 locations
Inotuzumab Ozogamicin in Treating Younger Patients with B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Active
Location: 139 locations
Testing the use of Daratumumab-Hyaluronidase in Persistent or Recurrent T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) following Treatment with Chemotherapy
Status: Active
Location: 128 locations
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants with Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Status: Active
Location: 108 locations
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
Status: Active
Location: 47 locations
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
Status: Active
Location: 34 locations
A Study to find the Highest Dose of Imetelstat in Combination with Fludarabine and Cytarabine for Patients with AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
Status: Active
Location: 19 locations
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Status: Active
Location: 20 locations
Molecular and Clinical Risk Directed Therapy for Infants and Young Children with Newly Diagnosed Medulloblastoma
Status: Active
Location: 10 locations
Revumenib, Azacitidine, and Venetoclax for the Treatment of Pediatric and Young Adult Patients with Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
Status: Active
Location: 10 locations
Talazoparib in Combination with Chemotherapy for the Treatment of Pediatric Patients with Relapsed or Refractory AML, the PARPAML Trial
Status: Active
Location: 10 locations
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Status: Active
Location: 8 locations
Zanubrutinib in Combination with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone and High-Dose Methotrexate for the Treatment of Patients with Large B-cell Lymphoma with Central Nervous System Involvement
Status: Active
Location: 8 locations
Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy for the Treatment of Metastatic, Unresectable or Relapsed Osteosarcoma, OstEvo Trial
Status: Active
Location: 7 locations
Total Therapy for Infants with Acute Lymphoblastic Leukemia, The TINI 2 Study
Status: Active
Location: 7 locations
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
Status: Active
Location: 12 locations
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Status: Active
Location: 8 locations
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults with Blood Cancers Undergoing Donor Stem Cell Transplant
Status: Active
Location: 6 locations
Adding Dasatinib or Venetoclax to Standard Chemotherapy for the Treatment in Children with T-Cell Acute Lymphoblastic Leukemia or T-Cell Lymphoma or Mixed Phenotype Acute Leukemia, the SJALL23T Trial
Status: Active
Location: 3 locations